Landfar Bio medicine Co

Landfar Bio medicine Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Landfar Bio medicine Co (000504.SZ) as of Nov 3, 2026 is -24.58. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 593.46 — a change of -104.14% (lower).

P/CF

-24.58

YoY

-104.14%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Landfar Bio medicine Co is 2025 -24.58 . P/CF (Price-to-Cash-Flow Ratio) of Landfar Bio medicine Co was 2024 593.46 . It decreases by -104.14% lower compared to the previous year.

The Landfar Bio medicine Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-187.31 CNY
Jan 1, 2019
195.89 CNY
Jan 1, 2020
-13.73 CNY
Jan 1, 2021
26.56 CNY
Jan 1, 2022
17.10 CNY
Jan 1, 2023
78.42 CNY
Jan 1, 2024
593.46 CNY
Jan 1, 2025
-24.58 CNY
The Landfar Bio medicine Co P/CF history
YEARP/CFYoY
-24.58-104.14%
593.46+656.78%
78.42+358.64%
17.10-35.63%
26.56-293.49%
-13.73-107.01%
195.89-204.58%
-187.31+212.12%
-60.01-69.19%
-194.79+17.57%
-165.69+89.88%
-87.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Landfar Bio medicine Co Stock analysis

What does Landfar Bio medicine Co do? NanHua Bio-medicine Co., Ltd. generates revenue through the manufacture and sale of pharmaceutical products, stem cell storage and technical services, stem cell treatment research, medical instrument purchasing and sales, as well as energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The company serves domestic customers seeking pharmaceuticals, stem cell services, medical instruments, and environmental solutions. Its biomedical segment focuses on stem cell-related offerings, while the energy conservation and environmental protection segment handles EMC, BT, and sewage treatment services. The firm operates exclusively within the domestic market, targeting businesses and consumers needing healthcare and environmental services. The company's revenue streams include pharmaceutical manufacturing, stem cell storage, medical instrument sales, and environmental services like EMC and BT projects. Domestic clients, including healthcare providers and environmental management firms, purchase these services and products. NanHua Bio-medicine Co., Ltd. leverages its domestic market presence to provide integrated solutions in healthcare and environmental sectors, with no international operations or external partnerships mentioned in its business description. Landfar Bio medicine Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Landfar Bio medicine Co stock

P/CF (Price-to-Cash-Flow Ratio) of Landfar Bio medicine Co is -24.58 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Landfar Bio medicine Co changed from 593.46 to -24.58, representing a -104.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Landfar Bio medicine Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Landfar Bio medicine Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Landfar Bio medicine Co

All Key Metrics — Landfar Bio medicine Co